BIOTRONIK Announces Completion of Enrollment in BIOHELIX-I Clinical Trial Evaluating Safety and Efficacy of PRO-Kinetic Energy Stent

Vascular Intervention

LAKE OSWEGO, Oregon, (PresseBox) - BIOTRONIK, a leading manufacturer of innovative cardio- and endovascular medical technology, announced that the final patient has been enrolled in the BIOHELIX-I clinical trial. The BIOHELIX-I trial is designed to evaluate the safety and efficacy of the PRO-Kinetic Energy coronary bare metal stent and supports US Food and Drug Administration approval for the treatment of coronary arteries. BIOTRONIK previously received CE mark approval for PRO-Kinetic Energy in 2009.

"The ultra-thin strut PRO-Kinetic Energy stent has a low profile and is extremely deliverable," commented national principal investigator for the study Dr. Saurabh Gupta, Director of the Cardiac Catheterization Laboratory at Oregon Health & Science University, Portland, Oregon. "I look forward to this innovative technology being available to all of my patients requiring treatment with a bare metal stent."

The BIOHELIX-I prospective, non-randomized, multi-center study (NCT01612767) has enrolled 329 patients in the US, Europe and South America. The primary endpoint for the study is the rate of target vessel failure nine months after stent implantation, a composite endpoint encompassing cardiac death, myocardial infarction and ischemia-driven target vessel revascularization.

PRO-Kinetic Energy is an ultrathin strut (60μm / 0.0024") cobalt chromium, bare metal stent, completely sealed with a thin layer of amorphous silicon carbide, called proBIO. This passive coating is known to reduce metal ion release from the stent, limiting adverse events post-implantation.

PRO-Kinetic Energy was previously evaluated for safety and effectiveness in the ENERGY registry, an all-comers registry, which studied more than 1,000 patients in Europe and Israel. The ENERGY registry studied more than 1,000 patients with a complex population of 39% B2/C lesions and 46% acute coronary syndrome patients. At 12 months, PRO-Kinetic Energy demonstrated a low 8.8% major adverse cardiac events (MACE) rate, including a 3.4% rate of target lesion revascularization (TLR). A sub-group analysis showed similarly low 12-month MACE rates in acute coronary syndrome (ACS) patients, elderly patients, and patients with small vessels or diabetes.

"The PRO-Kinetic Energy stent has already proven itself as an excellent treatment option for over half a million patients," said Dr. Daniel Buehler, President, BIOTRONIK Vascular Intervention. "The BIOHELIX-I trial brings BIOTRONIK one step closer to achieving its goal of offering US physicians a complete portfolio of innovative solutions for treating coronary disease."

About PRO-Kinetic Energy*

The PRO-Kinetic Energy bare metal coronary stent features ultrathin struts of only 60 µm and a unique double-helix design, resulting in exceptional flexibility and deliverability even in challenging vessels. The stent is made from a cobalt chromium alloy and is coated with proBIO, a silicon carbide layer that reduces metal ion release from the stent surface into the surrounding tissue. The PRO-Kinetic Energy Stent platform also forms the basis of the Orsiro Hybrid Drug-Eluting Stent** and the PK Papyrus** stent system for treating acute coronary artery perforation.

* CAUTION - Investigational device. Limited by United States law to investigational use.

Website Promotion


One of the world's leading manufacturers of cardio- and endovascular medical devices, BIOTRONIK is headquartered in Berlin, Germany, and represented in over 100 countries by its global workforce of more than 5,600 employees. Several million patients have received BIOTRONIK implants designed to save and improve the quality of their lives, or have been treated with BIOTRONIK coronary and peripheral vascular intervention products. Since its development of the first German pacemaker in 1963, BIOTRONIK has engineered many innovations, including BIOTRONIK Home Monitoring®; the world's first 4 F-compatible 200 mm peripheral stent*; Orsiro, the industry's first hybrid drug-eluting stent**; and the world's first implantable cardioverter-defibrillators with ProMRI® technology*.

** Not currently available in the United States.

For more information, visit:

Press releases you might also be interested in

Weitere Informationen zum Thema "Medizintechnik":

KI wird Mainstream – 5 Prognosen für 2018

Die Künst­li­che In­tel­li­genz wird nach Ein­schät­zung von Chri­s­to­phe Mar­ti­no­li, Vice Pre­si­dent Con­ti­nen­tal Eu­ro­pe beim glo­bal agie­ren­de Tech­no­lo­gie­un­ter­neh­men Wi­pro, ih­ren Sie­ges­zug die­ses Jahr wei­ter fort­set­zen. Fol­gen­de fünf IT-Trends iden­ti­fi­ziert Mar­ti­no­li für 2018.


Subscribe for news

The subscribtion service of the PresseBox informs you about press information of a certain topic by your choice at a choosen time. Please enter your email address to receive the email with the press releases.

An error occurred!

Thank you! You will receive a confirmation email within a few minutes.

I want to subscribe to the gratis press mail and have read and accepted the conditions.